



## JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office : T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA)

Fax : 0091-11-26498341, 26494708, Phone : 0091-11-26494519-24

CIN No:- L74899DL1978PLC009181

### JAGSONPAL PHARMACEUTICALS LIMITED

#### Audited Financial Results for the Quarter ended 31.03.2015

Rs. in lacs

PART-I Particulars	3 months ended 31.03.2015 Audited	3 months ended 31.12.2014 Unaudited	3 months ended 31.03.2014 Audited	12 Months ended 31.03.2015 Audited	12 Months Ended 31.03.2014 Audited
<b>1 Income from operations</b>					
a Net sales/Income from Operations (Net of excise duty)	3884.86	3242.86	3128.08	13815.09	14385.09
b Other Operating Income					
<b>Total Income from operations (net)</b>	<b>3884.86</b>	<b>3242.86</b>	<b>3128.08</b>	<b>13815.09</b>	<b>14385.09</b>
<b>2 Expenses</b>					
a Cost of materials consumed	1960.65	1567.32	1047.14	6383.36	5461.64
b Purchases of stock-in-trade	42.59	50.18	565.48	649.48	1294.90
c. Changes in inventories of finished goods, work	278.47	-48.08	-939.18	-164.55	-285.94
d. Employee benefits expenses	816.96	744.79	1022.02	3211.33	3783.43
e. Depreciation and amortisation expense	56.03	71.76	68.51	270.69	282.54
f. Other expenses	636.83	742.01	1061.74	2862.86	3063.27
<b>Total expenses</b>	<b>3791.53</b>	<b>3127.98</b>	<b>2825.71</b>	<b>13213.17</b>	<b>13599.84</b>
3 Profit from Operations before Other Income, Finance Cost and Exceptional items (1-2)	93.33	114.88	302.37	601.92	785.25
4 Other Income	5.55	0.41	6.07	11.10	6.07
5 Profit from ordinary activities before finance cost and Exceptional items (3+4)	98.88	115.29	308.44	613.02	791.32
6 Finance Cost	105.69	112.01	183.16	445.85	538.19
7 Profit from ordinary activities after finance cost but before Exceptional Items (5-6)	-6.81	3.28	125.28	167.17	253.13
8 Exceptional Items					
9 Profit(+)/Loss(-) from Ordinary Activities before tax (7+8)	-6.81	3.28	125.28	167.17	253.13
10 Tax expense	-13.60	0.66	3.08	50.06	41.06
11 Net Profit/Loss(-) from Ordinary Activities after tax (9-10)	6.79	2.62	122.20	117.11	212.07
12 Extraordinary Items (net of tax expense Rs. lacs)					
13 Net Profit(+)/Loss(-) for the period(11-12)	6.79	2.62	122.20	117.11	212.07
14 Share of profit/(Loss) of associates					
15 Minority interest					
16 Net Profit/(Loss) after taxes, minority interest	6.79	2.62	122.20	117.11	212.07
17 Paid up Eq. Sh. Cap.(Face value Rs. 5)	1309.90	1309.90	1309.90	1309.90	1309.90
18 Reserves excluding Revaluation reserves as per Balance sheet of pr. Accounting yr				7448.74	7298.31
19.i Earnings Per Share (before extraordinary items)					
a. Basic (Rs.)	0.03	0.01	0.47	0.45	0.81
b. Diluted (Rs.)	0.03	0.01	0.47	0.45	0.81
19.ii Earnings Per Share (after extraordinary items)					
a. Basic (Rs.)	0.03	0.01	0.47	0.45	0.81
b. Diluted (Rs.)	0.03	0.01	0.47	0.45	0.81





## JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office : T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA)

Fax : 0091-11-26498341, 26494708, Phone : 0091-11-26494519-24

### PART-II

#### A PARTICULARS OF SHAREHOLDING

1 Public Shareholding					
- Number of shares	8076680	8076680	8962360	8076680	8962360
- Percentage of Shareholding	30.83%	30.83%	34.21%	30.83%	34.21%
2 Promoter and promoter group shareholding					
A Pledged / encumbered					
- Number of shares					
- Percentage of shares (as a % of the total shareholding of Promoter and promoter group)					
- Percentage of shares (as a % of the total share capital of the Company)					
B Non - encumbered					
- Number of shares	18121320	18121320	17235640	18121320	17235640
- Percentage of shares (as a % of the total shareholding of Promoter and promoter group)	100%	100%	100%	100%	100%
- Percentage of shares (as a % of the total share capital of the Company)	69.17%	69.17%	65.79%	69.17%	65.79%

#### B INVESTOR COMPLAINTS

Pending at the beginning of the quarter	0	0	0	141	112
Received during the quarter	44	23	40		
Disposed of during the quarter	44	23	40		
Remaining unresolved at the end of the	0	0	0		

#### Notes

1. The Audited Financial Results for the Quarter ended 31.03.2015 have been reviewed by the Audit Committee. The Board of Directors has approved the financial Results at its meeting held on 29.05.2015
2. The figures for the quarter ended 31st March, 2015 represents the derived figures between the audited figures in respect of the year ended 31st March, 2015 and the unaudited published period to date figures upto 31st December, 2014 being the date of the end of the third quarter of the current year, which was subjected to a limited review.
3. In accordance with the companies Act, 2013 the company has revised the useful life of its fixed assets to comply with the useful life as mentioned under Schedule II of Companies Act, 2013. Based on transitional provision, given in Schedule II to the Companies Act, 2013, the carrying value of assets whose useful lives are already exhausted amounting to Rs 385.76 lacs (net of deferred tax of Rs 64.76 lacs) has been adjusted with the opening balance of Reserve. Had there been no change in useful lives of fixed assets, the charge to the statement of profit and loss would have been lower by Rs 19.62 Lacs.
4. The Company is operating only in the Pharmaceuticals segment and hence compliance has been made under AS-17.
5. The net effect of the deferred taxation for the Quarter as per AS-22 has been taken.
6. Previous year figures have been regrouped / rearranged wherever necessary.
7. The Board has recommended today, a final dividend of Rs 0.10 per share(2%) subject to approval of the shareholders at the ensuing Annual General Meeting.

By Order of the Board  
For Jagsonpal Pharmaceuticals Limited



Rajpal Singh Kochhar  
Managing Director  
DIN No 00059492

Place : New Delhi  
Date : 29.05.2015

## Statement of Assets and Liabilities

Rs. In lacs

Rs. In lacs

A	As at	As at	B	As at	As at
	31.03.2015	31.03.2014		31.03.2015	31.03.2014
<b>EQUITY AND LIABILITIES</b>			<b>ASSETS</b>		
1 Shareholders' funds			1 Non-current assets		
(a) Share Capital	1309.90	1309.90	(a) Fixed Assets	5193.03	5872.74
(b) Reserves and surplus	8232.66	8548.97	(b) Goodwill	3.00	3.00
Sub-total - Shareholders' funds	9542.56	9858.87	(c) Non-current investments	0.05	0.05
2 Share application money pending allotment	0.00	0.00	(d) Deferred tax assets (net)	0.00	0.00
3 Minority interest	0.00	0.00	(e) Long term loans and advance	646.62	618.52
4 Non-current liabilities			(f) Other non-current assets	0.00	0.00
(a) Long term borrowings		0.00	Sub-total - Non-current assets	5842.70	6494.31
(b) Deferred tax liabilities (net)	360.26	408.39	2 Current assets		
(c) Other long term liabilities	0.00	0.00	(a) Current investments		
(d) Long term provisions	0.00	0.00	(b) Inventories	3306.20	3058.92
Sub-total - Non-current liabilities	360.26	408.39	(c) Trade receivables	4488.87	4522.09
5 Current liabilities			(d) Cash and Cash equivalents	1501.61	1260.42
(a) Short term borrowing	3931.05	3595.76	(e) Short term loans and advance	282.62	289.98
(b) Trade payables	786.89	508.45	(f) Other current assets	0.00	0.00
(c) Other current liabilities	624.45	548.10	Sub-Total - Current assets	9579.30	9131.41
(d) Short term provisions	176.79	706.15	<b>TOTAL - ASSETS</b>	<b>15422.00</b>	<b>15625.72</b>
Sub-Total - Current liabilities	5519.18	5358.46			
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>15422.00</b>	<b>15625.72</b>			

For Jaganpal Pharmaceuticals Limited

Certified True Copy  
For Jaganpal Pharmaceuticals Ltd.

  
Company Secretary

  
Director



## JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office : T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA)

Fax : 0091-11-26498341, 26494708, Phone : 0091-11-26494519-24

CIN : L74899DL1978PLC009181

### Particulars Under Clause 20 of the Listing Agreement for Year Ended March 31st, 2015

S- NO.	PARTICULARS	YEAR ENDED	
		31.03.2015	31.03.2014
			<b>Rs. In Lacs</b>
01	Total Turnover	13815.09	14385.09
02	Gross Profit/Loss (EBIDTA_ before exceptional Items)	437.86	535.67
03	Provision for Depreciation	270.69	828.54
04	Tax Provisions	50.06	41.06
05	Net Profit/Loss	117.11	212.07
06	Appropriated from reserves	-	-
07	Appropriated from Capital Profit	-	-
08	Appropriated from accumulated profits of past year	-	-
09	Dividend on Equity Share (Including Corporate Dividend Tax on Dividend)	31.44	453.25
10	Paid up equity capital	1309.90	1309.90

Certified True Copy  
For JAGSONPAL PHARMACEUTICALS LIMITED



**R. K. KAPOOR**  
Company Secretary Cum Compliance Officer